Moffitt’s chief information security officer named fellow to America’s cybersecurity think tank

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Moffitt Cancer Center’s chief information security officer will join a group of experts charged with protecting and enhancing national cybersecurity.

Dave Summitt has been named a Fellow of the Institute for Critical Infrastructure Technology, the nation’s leading cybersecurity think tank.

The institute focuses on safeguarding national security, economic security, and national public health and safety under the Department of Homeland Security. As an ICIT Fellow, Summitt will share his expertise with the cyber and national security community by participating in thought leadership and educational engagements.

ICIT provides objective, nonpartisan advisory to the Senate, House of Representatives, and federal government leaders in civilian, defense and intelligence agencies. Research conducted in ICIT’s labs, and distributed through its publications, is used by United States leaders, embassies, allied governments, and critical infrastructure operators around the globe.

Summitt has been with Moffitt since 2015. He has more than 30 years of experience in the technology field, with over 13 years working directly in cybersecurity.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login